Characterization and in vivo evaluation of an inclusion complex of oridonin and 2-hydroxypropyl-β-cyclodextrin

Drug Development and Industrial Pharmacy

Volumn 34, Issue 6, 2008, Pages 632-641

  Yan, Zhiqiang ^a   Xu, Wen ^b   Sun, Jin ^a   Liu, Xiaohong ^a   Zhao, Yanping ^a   Sun, Yinghua ^a   Zhang, Tianhong ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

2 hydroxypropyl cyclodextrin; Characterization; Inclusion complex; Oridonin; Pharmacokinetics; Tissue distribution

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ORIDONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DISTRIBUTION; DRUG SCREENING; DRUG SOLUBILITY; DRUG TISSUE LEVEL; FREEZE DRYING; HEART; IN VIVO STUDY; INFRARED SPECTROSCOPY; KIDNEY; LUNG; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; RAT; SPLEEN; TISSUE DISTRIBUTION; X RAY DIFFRACTION;

ANIMALS; AREA UNDER CURVE; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DITERPENES, KAURANE; EXCIPIENTS; FREEZE DRYING; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; RATS; RATS, WISTAR; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TISSUE DISTRIBUTION; X-RAY DIFFRACTION;

EID: 45849128338     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701834078     Document Type: Article

References (33)

1. Beker, O., Uijtendaal, E. V., Beijnen, J. H., Bult, A., & Underberg, W. J. M. (1991). Cyclodextrins in the pharmaceutical field. Drug Dev. Ind. Pharm., 17, 1503-1549.
2. Carpenter, T. O., Gerloczy, A., & Pitha, J. (1995). Safety of parenteral Hydroxypropyl-β-cyclodextrin. J. Pharm. Sci. 84, 222-225.
3. Connors, K. A. (1997). The stability of cyclodextrin complexes in solution. Chem. Rev., 97, 1325-1358.
4. Dollo, G., Thompson, D. O., Le Corre, P., Chevanne, F., & LeVerge, R. (1998). Inclusion complexation of amide-typed local anesthetics with β-cyclodextrin and its derivatives. III: Biopharmaceutics of bupivacaine-SBE7-βCD complex following percutaneous sciatic nerve administration in rabbits. Int. J. Pharm., 164, 11-19.
5. Frijlink, H. W., Visser, J., Hefting, N. R., Oosting, R., Meijer, D. K., & Lerk, C. F. (1990). The pharmacokinetics of beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin in the rat. Pharm. Res., 7, 1248-1252.
6. Frijlink, H. W., Franssen, E. J., Eissens, A. C., Oosting, R., Lerk, C. F., & Meijer, D. K. (1991). The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharm. Res., 8, 380-384.
7. Fuji, K., Node, M., Sai, M., Fujita, E., Takeda, S., & Unemi, N. (1989). Terpenoids. LIII. Antitumor activity of trichorabdals and related compounds. Chem. Pharm. Bull., 37, 1472-1476.
8. Hahimoto, S., & Thomas, J. K. (1985). Fluorescence study of pyerne and naphthalene in cyclodextrin-amphiphile complex system. J. Am. Chem. Soc., 107, 4655-4662.
9. Higuchi, T., & Connors, K. A. (1965). Phase-solubility techniques. Adv. Anal. Chem. Inst., 4, 117-212.
10. Higuchi, T., & Kristiansen, H. (1970). Binding specificity between small organic solutes in aqueous solution: Classification of some solutes into two groups according to binding tendencies. J. Pharm. Sci.-US., 59, 1601-1608.
11. Ikezoe, T., Chen, S. S., Tong, X. J., Heber, D., Taguchi, H., & Koeffler, H. P. (2003). Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int. J. Oncol., 23, 1187-1193.
12. Kim, J. H., Lee, S. K., Ki, M. H., Choi, W. K., Ahn, S. K., Shin, H. J., & Hong, C. I. (2004). Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-β- cyclodextrin. Int. J. Pharm., 272(1-2), 79-89.
13. Liu, J., Qiu, L., Gao, J., & Jin, Y. (2006). Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrin. Int. J. Pharm., 312(1-2), 137-143.
14. Loftsson, T., & Brewster, M. E. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci., 85, 1017-1025.
15. Loftsson, T., Hreinsdottir, D., & Masson, M. (2005). Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm., 302(1-2), 18-28.
16. Loftsson, T., Masson, M., & Sigurjonsdottir, J. F., (1999). Methods to enhance the complexation efficiency of cyclodextrins. S.T.P. Pharma. Sci., 9, 237-242.
17. Marks, L. S., Dipaola, R. S., Nelson, P., Chen, S., Heber, D., & Belldegrun, A. S. (2002). PC-SPES: Herbal formulation for prostate cancer. Urology, 60, 369-377.
18. Marques, H. M., Hadgraft, J., & Kellaway, I. W. (1990). Studies of cyclodextrin inclusion complexes, 1. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int. J. Pharm., 63, 259-266.
19. Osawa, L., Yasuda, H., Maruyama, T., Morita, H., Takeya, K., & Itokawa, H. (1994). Antibacterial trichorabdal diterpenes from Rabdosia trichocarpa. Phytochemistry, 36, 1287-1291.
20. Piel, G., Evrard, B., Van, H. T., & Delattre, L. (1999). Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution. Int. J. Pharm., 180, 41-45.
21. Rajewski, R. A., & Stella, V. J. (1996). Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci., 85, 1142-1169.
22. Saenger, W. (1980). Cyclodextrin inclusion compounds in research and industry. Angew. Chem. Int. Edit., 19, 344-362.
23. Stella, V. J., Rao, V. M., Zannou, E. A., & Zia, V. V. (1999). Mechanisms of drug release from cyclodextrin complexes. Adv. Drug. Deliv. Rev., 36, 3-16.
24. Turro, N. J., Okubo, T., & Chung, C. J. (1982). Analysis of static and dynamic host-guest associations of detergents with cyclodextrins via photoluminescence methods. J. Am. Chem. Soc., 104, 1789-1794.
25. Xing, J., Zhang, D. R., & Tan, T. W. (2007). Studies on the oridonin-loaded poly (d,l-lactic acid) nanoparticles in vitro and in vivo. Int. J. Biol. Macromol., 40, 153-158.
26. Xu, W., Sun, J., Zhang, T., Tang, J., Li, H., Fang, J., Chen, D., & He, Z., (2006a). A rapid HPLC/ESI-MS method for the quantitative determination of oridonin in rat plasma. Pharmazie., 61, 757-759.
27. Xu, W., Sun, J., Zhang, T., Ma, B., Cui, S. M., Chen, D., & He, Z. (2006b). Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. Acta Pharmacol Sin., 27, 1642-1646.
28. Yuan, K., Wu, C. Z., Zhang, X. M., Sun, W., & Zheng, L. (2004). HPLC in quantitative determination of oridonin and ponicidin in the Rabdosia rubescens. Chin. J. MAP., 21, 213-215.
29. Zhang, C. L., Wu, L. J., Tashiro, S., Onodera, S., & Ikejima, T. (2003). Oridonin induced Hela cell apoptosis through caspase pathway. Chin. Pharmacol. Bull., 19, 525-529.
30. Zhang, C. L., Wu, L. J., Zuo, H. J., Tashiro, S., Onodera, S., & Ikejima, T. (2004). Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated Kinase. J. Pharmacol. Sci., 96, 155-163.
31. Zhang, Y., Wang, J., Lou, L. G., Zhang, T. M., Hou, J. W., & Xin, W. J. (1999). Scavenging effect of oridonin on active oxygen free radicals. Henan Med. Res., 8, 100-104.
32. Zingone, G., & Rubessa, F. (2005). Preformulation study of the inclusion complex warfarin-β-cyclodextrin. Int. J. Pharm., 291(1-2), 3-10.
33. Zuo, Z., Tam, Y. K., Diakur, J., & Wiebe, L. I. (2002). Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat. J. Pharm. Pharm. Sci., 5, 292-298.